Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

14.57USD
21 Sep 2018
Change (% chg)

$0.54 (+3.85%)
Prev Close
$14.03
Open
$14.20
Day's High
$14.95
Day's Low
$13.90
Volume
1,296,991
Avg. Vol
185,210
52-wk High
$14.95
52-wk Low
$3.55

Chart for

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $778.32
Shares Outstanding(Mil.): 53.42
Dividend: --
Yield (%): --

Financials

  FATE.OQ Industry Sector
P/E (TTM): -- 108.45 32.71
EPS (TTM): -1.18 -- --
ROI: -85.81 1.54 12.72
ROE: -106.45 0.30 14.84

BRIEF-Fate Therapeutics Qtrly Loss Per Share $0.27

* FATE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

May 10 2018

BRIEF-Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million

* FATE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (https://bit.ly/2KD5gGz) Further company coverage:

May 04 2018

Earnings vs. Estimates